What’s new on the horizon for lipoprotein(a) therapies?
Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights
15th Virtual Closed Scientific Expert Meeting of the Editorial Board
Critical questions in PCSK9 research
Where next for cost-effectiveness analysis of combination LDL lowering therapies?
Dr Dhruv Kazi focuses on future considerations for these analyses.
Is a 'once-and-done' approach to LDL lowering feasible?
Prof Kiran Musunuru overviews latest developments with CRISPR base editing of PCSK9.
Should ACS patients start a PCSK9 inhibitor in hospital?
Prof Steve Nicholls (Monash University, Australia) puts data from PACMAN-AMI, HUYGENS & GLAGOV in perspective.
Related reports:
ACC.22 Scientific Sessions
2-4 April, Washington DC
For reportage and expert analysis from: